Funding

MEDIPOST

United States · Biotech

MEDIPOST develops stem-cell therapies derived from donated umbilical cord blood.

Visit medi-post.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Undisclosed$140MCrescendo Equity Partners — Role not disclosedSkylake Equity Partners — Role not disclosed

Investors

Crescendo Equity PartnersUndisclosedSkylake Equity PartnersUndisclosed

Coverage

Jan 9, 2026MEDIPOST · Undisclosed

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcesprojectstartups.com ↗